Mediar commences dosing in Phase II trial of MTX-463 for IPF
Change from baseline in forced vital capacity at 24 weeks is the trial’s primary endpoint.
Clinical Trials
Valneva reports data from Phase II chikungunya vaccine trial in children
Avenzo begins Phase I/II trial of CDK4 selective inhibitor for breast cancer
Enrolment concludes in Halia’s Phase IIa trial of HT-6184 for MDS
Iambic concludes dose escalation in Phase I/Ib trial of IAM1363
Moleculin announces efficacy results from trial of Annamycin for STS lung mets
TRex Bio doses first healthy volunteer in trial of atopic dermatitis treatment
ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer
